Literature DB >> 4052067

Inhibition of liver lipase in vivo leads to induction of de novo cholesterol synthesis in rat liver.

H Jansen.   

Abstract

Rats were injected with control-gamma-globulins or anti-liverlipase. The anti-liverlipase treatment resulted in a 69-78% inhibition of the salt-resistant lipase activity (liver lipase) in the liver. De novo cholesterol synthesis was significantly higher in slices of livers from anti-liverlipase treated rats than from control-gamma-globulin injected rats. The anti-liverlipase treatment also affected all plasma lipoprotein fractions. If the rats had been fed a cholestyramine containing diet no effect of anti-liverlipase on cholesterol synthesis was found. In these rats the effects on plasma lipoprotein fractions were more pronounced than in the control fed rats.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4052067     DOI: 10.1016/0006-291x(85)91275-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Effect of essential fatty acid deficiency on the size and distribution of rat plasma HDL.

Authors:  K E Lowe; S Pelkey; M A Williams; A V Nichols
Journal:  Lipids       Date:  1988-02       Impact factor: 1.880

2.  Maturation and secretion of rat hepatic lipase is inhibited by alpha1B-adrenergic stimulation through changes in Ca2+ homoeostasis: thapsigargin and EGTA both mimic the effect of adrenaline.

Authors:  B P Neve; A J Verhoeven; I Kalkman; H Jansen
Journal:  Biochem J       Date:  1998-03-01       Impact factor: 3.857

3.  Lipoprotein pattern and plasma lipoprotein lipase activities in patients with primary biliary cirrhosis. Relationship with increase of HDL2 fraction in Lp-X-positive and Lp-X-negative subjects.

Authors:  G Baldo-Enzi; M R Baiocchi; M Grotto; A R Floreani; M Zagolin; M Chiaramonte; F Cera; R Fellin
Journal:  Dig Dis Sci       Date:  1988-10       Impact factor: 3.199

4.  Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo.

Authors:  Weijun Jin; John S Millar; Uli Broedl; Jane M Glick; Daniel J Rader
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.